Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery
A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
- Pfizer Investigational Site
-
-
Florida
-
Saint Petersburg, Florida, United States, 33713
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Pfizer Investigational Site
-
Timonium, Maryland, United States, 21093
- Pfizer Investigational Site
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01107
- Pfizer Investigational Site
-
Springfield, Massachusetts, United States, 01199
- Pfizer Investigational Site
-
Springfield, Massachusetts, United States, 01104
- Pfizer Investigational Site
-
Springfield, Massachusetts, United States, 01109
- Pfizer Investigational Site
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Pfizer Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29202
- Pfizer Investigational Site
-
Columbia, South Carolina, United States, 29204
- Pfizer Investigational Site
-
Columbia, South Carolina, United States, 29212
- Pfizer Investigational Site
-
Orangeburg, South Carolina, United States, 29110
- Pfizer Investigational Site
-
-
Tennessee
-
Johnson City, Tennessee, United States, 37601
- Pfizer Investigational Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78209
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78240
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78205
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria:
- Diagnosed (or suspected to have) meniscus trauma of the knee requiring ambulatory arthroscopic knee surgery
- Willing to participate in study for 36 hours and come to follow-up visit 7 days post surgery
Exclusion Criteria:
Exclusion criteria:
- Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
- Received acetaminophen or low dose narcotic (vicodin/tylox) within 8 hours of surgery
- Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or intra-artcular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
|
400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
|
|
Placebo Comparator: B
|
Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total analgesic use (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Vital signs
Time Frame: Day 7
|
Day 7
|
|
Adverse events
Time Frame: Day 7
|
Day 7
|
|
Patient Assessment of Pain, according to visual analogue scale, after surgery at rest and flexion
Time Frame: 1, 2, 6, 8, 10, 12, 24, 36 hours
|
1, 2, 6, 8, 10, 12, 24, 36 hours
|
|
Time to analgesic use after surgery
Time Frame: 1, 2, 6, 8, 10, 12, 24, 36 hours
|
1, 2, 6, 8, 10, 12, 24, 36 hours
|
|
Number and percentage of patients taking HC/APAP after surgery
Time Frame: 1, 2, 6, 8, 10, 12, 24, 36 hours
|
1, 2, 6, 8, 10, 12, 24, 36 hours
|
|
Physical exam
Time Frame: Day 7
|
Day 7
|
|
Laboratory evaluation
Time Frame: Day 7
|
Day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
Other Study ID Numbers
- A3191067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.